Long-term fetal microchimerism in peripheral blood mononuclear cell subsets in healthy women and women with scleroderma.

Fetal CD34(+) CD38(+) cells have recently been found to persist in maternal peripheral blood for many years after pregnancy. CD34(+) CD38(+) cells are progenitor cells that can differentiate into mature immune-competent cells. We asked whether long-term fetal microchimerism occurs in T lymphocyte, B lymphocyte, monocyte, and natural-killer cell populations of previously pregnant women. We targeted women with sons and used polymerase chain reaction for a Y-chromosome-specific sequence to test DNA extracted from peripheral blood mononuclear cells (PBMC) and from CD3, CD19, CD14, and CD56/16 sorted subsets. We also asked whether persistent microchimerism might contribute to subsequent autoimmune disease in the mother and included women with the autoimmune disease scleroderma. Scleroderma has a peak incidence in women after childbearing years and has clinical similarities to chronic graft-versus-host disease that occurs after allogeneic hematopoietic stem-cell transplantation, known to involve chimerism. Sixty-eight parous women were studied for male DNA in PBMC and 20 for PBMC subsets. Microchimerism was found in PBMC from 33% (16 of 48) of healthy women and 60% (12 of 20) women with scleroderma, P =.046. Microchimerism was found in some women in CD3, CD19, CD14, and CD56/16 subsets including up to 38 years after pregnancy. Microchimerism in PBMC subsets was not appreciably more frequent in scleroderma patients than in healthy controls. Overall, microchimerism was found in CD3, CD19, and CD14 subsets in approximately one third of women and in CD56/16 in one half of women. HLA typing of mothers and sons indicated that HLA compatibility was not a requirement for persistent microchimerism in PBMC subsets. Fetal microchimerism in the face of HLA disparity implies that specific maternal immunoregulatory pathways exist that permit persistence but prevent effector function of these cells in normal women. Although microchimerism in PBMC was more frequent in women with scleroderma than healthy controls additional studies will be necessary to determine whether microchimerism plays a role in the pathogenesis of this or other autoimmune diseases.

[1]  D. Furst,et al.  Microchimerism and HLA-compatible relationships of pregnancy in scleroderma , 1998, The Lancet.

[2]  P. Matzinger,et al.  The maternal immune system's interaction with circulating fetal cells. , 1997, Journal of immunology.

[3]  I. Sargent,et al.  Two-way cell traffic between mother and fetus: biologic and clinical implications. , 1996, Blood.

[4]  J. Nelson,et al.  Maternal-fetal immunology and autoimmune disease: is some autoimmune disease auto-alloimmune or allo-autoimmune? , 1996, Arthritis and rheumatism.

[5]  G. Weil,et al.  Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Alferink,et al.  T Cell Awareness of Paternal Alloantigens During Pregnancy , 1995, Science.

[7]  C. Rodeck,et al.  Y chromosome sequence DNA amplified from peripheral blood of women in early pregnancy , 1994, The Lancet.

[8]  H. Claman The Immunology of Human Pregnancy , 1993, Humana Press.

[9]  Rebecca Lynn Johnson,et al.  HLA homozygosity and the risk of related-donor transfusion-associated graft-versus-host disease. , 1993, Transfusion medicine reviews.

[10]  M. Sampietro,et al.  Detection of single-copy fetal DNA sequence from maternal blood , 1990, The Lancet.

[11]  N. Nussinovitch,et al.  The role of blood from HLA-homozygous donors in fatal transfusion-associated graft-versus-host disease after open-heart surgery. , 1989, The New England journal of medicine.

[12]  D. Furst,et al.  A syndrome resembling progressive systemic sclerosis after bone marrow transplantation. A model for scleroderma? , 1979, Arthritis and rheumatism.

[13]  R. Owen IMMUNOGENETIC CONSEQUENCES OF VASCULAR ANASTOMOSES BETWEEN BOVINE TWINS. , 1945, Science.